Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to understand the emotional and sexual well-being of women with a rare uterine condition

NCT ID NCT07186764

Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, a rare condition where the uterus and vagina are underdeveloped, affects women's overall quality of life, sexual health, and mental well-being. Researchers will compare 102 women with MRKH to a control group using questionnaires. The goal is to better understand the challenges these women face and improve their care and support.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 102 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Mayer-Rokitansky-Küster-Hauser syndrome and patients followed in gynecological consultation without the presence of this syndrome

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For Mayer-Rokitansky-Küster-Hauser patients: * Patient over 18 and under 50 * Confirmed diagnosis of Mayer-Rokitansky-Küster-Hauser syndrome * Diagnosis announced more than 1 year ago * Patient treated by the CRMR PGR * Patient affiliated with or benefiting from a social security scheme * Fluency in French * For the control population: * Patient over 18 and under 50 * Patient affiliated with or benefiting from a social security scheme * Fluency in French Exclusion Criteria: * For Mayer-Rokitansky-Küster-Hauser patients: * Minors over 50 years of age * Recent diagnosis \< 1 year * Other causes of uterine or vaginal aplasia, surgical or congenital • Patients benefiting from a legal protection measure (guardianship, curatorship, legal protection) * Patients unable to understand or answer the questionnaires * For the control population: * Minors over 50 years of age * Patients benefiting from a legal protection measure (guardianship, curatorship, legal protection) * Patients unable to understand or answer the questionnaires

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MRKH syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Mayer-Rokitansky-Kuster-Hauser syndrome mullerian aplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MRKH syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Service d'Endocrino-gynéco-pédiatrie, Hôpital des Enfants, 330 Avenue de Grande Bretagne

    RECRUITING

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.